Rovalpituzumab tesirine for the treatment of relapsed or refractory small cell lung cancer

featured image
Therapeutic Areas: Lung and Respiratory Cancer
Year: 2017

Rovalpituzumab tesirine is a new antibody‐drug conjugate that binds to delta‐like protein 3(DLL3) present in the cancer cells of most small cell lung cancer patients. This drug works by attacking and killing cancer cells, limiting the growth of tumours due to small cell lung cancer (SCLC). This drug is being currently studied as third line therapy for patients that get worse after treatment with other therapies such as chemotherapy or radiotherapy.